SERO Serologicals (MM)

Serologicals Corporation (NASDAQ:SERO) today announced that it is scheduled to give an investor presentation at the 2005 First Analysis Investment Conference on November 17, 2005. David A. Dodd, President and Chief Executive Officer for Serologicals Corporation, will be making the presentation, scheduled for 10:35 a.m. (ET) at The New York Palace Hotel in New York City. The presentation will be web cast live (audio only) and can be accessed through the Company's website at www.serologicals.com or at http://www.wsw.com/webcast/fa3/sero/. Serologicals Corporation (NASDAQ:SERO), headquartered in Atlanta, Georgia, is a global provider of biological products, enabling technologies and services to a diverse customer base that includes major life science companies and leading research institutions. Our customers use our products, technologies and services in a wide variety of their activities, including basic research, drug discovery, diagnosis and biomanufacturing. Our products, technologies and services are essential tools for research in key disciplines, including neurology, oncology, hematology, immunology, cardiology, proteomics, infectious diseases, cell signaling and molecular biology. In addition, the Company is the world's leading provider of monoclonal antibodies for the blood typing industry. Serologicals employs a total of more than 1,000 people worldwide in three Serologicals' companies: Chemicon International, headquartered in Temecula, CA, Upstate Group, LLC, headquartered in Charlottesville, VA. and Celliance Corporation, headquartered in Atlanta, GA. For more information, please visit our website: www.serologicals.com. Serologicals is a registered trademark of Serologicals Royalty Company.